top of page

FDA approves LEMBAZ for infantile-onset NPC: what the news means for Australia

10 hours ago
3 min read

The U.S. Food and Drug Administration (FDA) has approved LEMBAZ™ (adrabetadex) for adults and children with Niemann–Pick disease type C (NPC) whose neurological symptoms began before age six and who weigh at least 7 kg. The FDA says LEMBAZ is the first treatment shown to reduce the risk of death in this group. For Australian families, this is a U.S. approval and does not confirm Australian registration or availability. This article explains what the FDA decision means, the evidence behind it, current Australian regulatory status, and where families can find reliable updates and discuss treatment questions with their specialist team.

Logo of Beren Therapeutics

A milestone shaped by years of work


This announcement marks an important moment for the global NPC community. It reflects years of persistence by families, advocates, clinicians and researchers who have worked to move treatment research forward.


For the Australian community, adrabetadex has a particularly long history. Before it was called adrabetadex, it was known as VTS-270. Australian families and advocates worked with clinicians to persuade the company developing it, Vtesse, to include Australian trial sites. In 2017, Vtesse announced that the first trial participants in Australia had received the medicine. The trial included sites at Prince of Wales Hospital, Monash Medical Centre, Royal Melbourne Hospital and Royal Perth Hospital. ANPDF founder Mandy Whitechurch described the effort as six years of perseverance.

Proud trial participant at the Royal Melbourne Hospital.
Proud trial participant at the Royal Melbourne Hospital.

The program later moved to Mandos, which took over from Mallinckrodt. Mandos continued the research and offered an Expanded Access Program for some patients after the trial. ANPDF shared Mandos updates with the Australian community, including information about the program and its supply plans. In 2026, Beren Therapeutics explained that Mandos is its wholly owned subsidiary and that this work would continue under the Beren name.


This history is a reminder of what families and advocates can help make possible. It also reflects the many people who have contributed across different stages of the program.


What the FDA approval covers

The FDA approved LEMBAZ for people with NPC whose neurological symptoms began before their sixth birthday and who weigh at least 7 kg. It is given by a trained health professional as an injection into the spinal canal every two weeks.


The FDA reviewed survival data from 36 people treated across three clinical studies and an Expanded Access Program, comparing them with a matched external control group. It reported a 55% reduction in the risk of death in the treated group. The reported median survival was 8.5 years in the treated group and 4.9 years in the control group. These are group-level findings from the analysis reviewed by the FDA; they cannot predict an individual person’s outcome.


LEMBAZ carries a boxed warning for hearing impairment, including permanent hearing loss. The FDA says hearing assessments are needed before and during treatment. Anyone with questions about LEMBAZ or its risks should speak with their specialist team.


What this means for people in Australia

The FDA decision applies in the United States. It does not by itself mean LEMBAZ is approved or available in Australia. Medicines need Australian market authorisation from the Therapeutic Goods Administration (TGA) to be supplied here.


At the time of writing, ANPDF has not found a public announcement confirming TGA registration or Australian availability of LEMBAZ. Beren has said it expects the medicine to be available at treatment sites in the United States in early December; this is a U.S. timeline, not an Australian availability date.


We know this news may bring hope, questions and strong feelings for families. The approval is an important step, but what it means for Australian access remains unclear. ANPDF will share confirmed information as it becomes available.


For now, please discuss treatment questions with your specialist team and don’t change or stop any current treatment without medical advice. You can contact ANPDF for general information or support connecting with the community.


To join our fight, as well as fund vital research for a cure, support the Australian NPC Disease Foundation in its goals of "Research. Cure. Persevere."


Ways to support NP-C in Australia:


References:

  1. U.S. Food and Drug Administration. (2026, November 17). FDA approves first drug shown to help patients with infantile-onset Niemann-Pick disease type C live longer. FDA announcement

  2. Beren Therapeutics. (2026, November 17). Beren Therapeutics announces U.S. FDA approval of LEMBAZ™ (adrabetadex). Beren announcement

  3. Therapeutic Goods Administration. Application and market authorisation for prescription medicines. TGA information


Related Posts

See All
Xenpozyme supply update for the ASMD community

ANPDF shares the latest Xenpozyme supply update from INPDA and Sanofi, including where Australian families can check current information. If you have concerns about treatment or supply, please contact

 
 
 

Comments

Rated 0 out of 5 stars.
No ratings yet

Commenting on this post isn't available anymore. Contact the site owner for more info.
bottom of page